New cocktail aims to starve pancreatic tumors
NCT ID NCT05034627
First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 3 times
Summary
This early-phase trial tests two drugs together in 15 people with advanced pancreatic cancer. One drug, calaspargase pegol-mknl, lowers a nutrient that cancer cells need to grow. The other, cobimetinib, blocks a protein that helps cancer cells survive. The goal is to find a safe dose and see if the combination can control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- calaspargase pegol-mknl and cobimetinib
- What this could lead to
- If it works, this could point toward a new treatment option for advanced pancreatic cancer by starving cancer cells of a key nutrient.
- What could go wrong
- This is a very early, small Phase 1 trial focused on safety and dosing, not effectiveness. The combination may cause serious side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Can a targeted antibody give pancreatic cancer chemo a boost?
- Can High-Dose vitamin c boost chemo against pancreatic cancer?
- Four-Drug cocktail aims to shrink pancreatic tumors before surgery
- Could a Decades-Old parasite drug help fight pancreatic cancer?
- Could a nerve zap stop cancer wasting? early trial tests device for cachexia